Technical overview on the MiStent coronary stent.

Area of Science:

• Cardiovascular Medicine
• Biomaterials Science
• Interventional Cardiology

Background:

• Drug-eluting stents (DES) improve percutaneous coronary intervention (PCI) but often use permanent polymers.
• Permanent polymers can cause adverse vascular reactions, including inflammation, delayed healing, and stent thrombosis.
• Bioabsorbable polymer DES aim to mitigate risks associated with long-term polymer exposure.

Purpose of the Study:

• To evaluate the MiStent Sirolimus-Eluting Absorbable Polymer Coronary Stent System (MiStent SES) as an alternative to permanent polymer DES.
• To highlight the benefits of a solvent-free drug and polymer coating technology.
• To assess the sustained drug release profile and absorption characteristics of the MiStent SES.

Main Methods:

• The MiStent SES utilizes a thin-strut cobalt chromium alloy stent platform.
• A solvent-free supercritical fluid technology applies crystalline sirolimus and polylactide-co-glycolic acid (PLGA) coating.
• The stent platform and coating are designed for controlled drug elution and polymer absorption.

Main Results:

• The PLGA coating is fully absorbed within 90 days.
• Crystalline sirolimus remains in the tissue for up to 9 months after polymer absorption.
• The solvent-free application avoids drug burst and ensures uniform drug delivery.

Conclusions:

• The MiStent SES offers a novel approach to DES by using a bioabsorbable polymer and crystalline drug formulation.
• This technology potentially provides improved clinical benefits by ensuring sustained drug presence and minimizing polymer-related risks.
• The unique drug release profile may lead to better long-term outcomes in PCI.